SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 ($QQQ) is experiencing high volatility as traders grapple with mixed signals and a sharp intraday reversal. Community discussions center around potential market manipulation, the impact of $NVDA's earnings, and speculation about future interest rate decisions. Some traders are anticipating a bounce, while others fear a deeper correction, creating uncertainty around the direction of the tech-heavy ETF.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as investors discuss its latest earnings report, with community members debating whether positive results will be enough to overcome negative market sentiment. Discussions also include speculation about potential upgrades, institutional interest, and comparisons to similar companies like SoFi. Some traders are closely watching for guidance from the earnings call and anticipate increased volatility.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards as the community expresses concerns over its large Ethereum holdings amidst a broader crypto downturn, with many pointing to unrealized losses and the potential impact of upcoming earnings. Discussions revolve around the company's strategy, particularly regarding staking, and whether CEO Tom Lee can address investor anxieties. Some traders speculate on coordinated short attacks, while others see a buying opportunity if the company starts staking.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid a sharp market reversal driven by concerns about future rate cuts and disappointing reactions to tech earnings, sparking community discussion on potential support levels and market manipulation. Community members are debating whether this is a temporary pullback or the start of a larger correction, with some pointing to potential negative catalysts while others anticipate a bounce. Discussions also involve the impact of political factors and the unwinding of carry trades on market sentiment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid a volatile trading session, driven by reactions to increased capital expenditure plans and anticipation for Nvidia's upcoming earnings report. Community members are actively debating whether the recent pullback presents a buying opportunity or signals an overbought condition, with some citing strong fundamentals and rising memory prices, while others point to potential overvaluation and cyclical concerns within the semiconductor sector.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders assess its recent pullback and potential for a rebound, with some noting its relative strength compared to tech. Community members are actively discussing key support and resistance levels, put/call flows, and the potential impact of upcoming economic data and $NVDA earnings on small caps. Overall sentiment appears mixed, with both bullish and bearish viewpoints being shared.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors assess its stability amid broader market uncertainty and an upcoming earnings report, with some highlighting its potential to capture market share from competitors. The community is also discussing Walmart's AI initiatives and the impact of consumer spending trends on its performance. Additionally, Walmart's recent announcement of a CEO transition is being monitored for its potential impact on the company's strategic direction.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards as the broader crypto market experiences a pullback, sparking discussions about potential support levels and whether this is a temporary dip or a longer-term correction. The community is debating the influence of large holders and potential market manipulation, while also considering historical patterns and future catalysts. Some traders are expressing concern and urging caution, while others see this as a buying opportunity.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending downwards as Bitcoin's recent volatility sparks concerns about the company's heavy investment in the cryptocurrency and potential margin calls. The community is actively discussing downside risk, potential bankruptcy scenarios, and the impact of prominent figures like Jim Cramer and Michael Saylor on the stock's future, questioning its correlation with Bitcoin's price movements.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, with the community debating potential causes such as market manipulation, overall market conditions, and concerns about profitability ahead of earnings; some traders are pointing to the company's recent news regarding its AI chip, while others express frustration with the stock's performance despite positive developments for the EV maker.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sunshine Biopharma (SBFM) rose 11% on Thursday morning after the company announced that its Canadian unit, Nora Pharma, launched a generic version of Bristol-Myers Squibb’s Pravachol.The drug, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/10/20251016_SBFM_Press-Release_Launches-Pravastatin.pdf">called</a> Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.Nora Pharma’s Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, and comes in bottles of 100 tablets.Sunshine Biopharma said that the Canadian market of cholesterol-lowering drugs is estimated to reach $582 million by the end of 2025 and $1.07 billion by 2033.Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada, and more than 12 additional drugs are scheduled to be launched in 2026. The company is also seeking to develop drug candidates in the treatment of liver cancer and coronavirus infections.On Stocktwits, retail sentiment around SBFM stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_10_55_53_AM_png_97567a6c3b.webp" alt="SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company has a bright future.<stembedurl>https://stocktwits.com/Knowledgeworthmore/message/632572691</stembedurl>Another said that they intend to hold the stock long term.<stembedurl>https://stocktwits.com/BanditKnight47/message/632549060</stembedurl>In July, Sunshine Bioopharma <a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-soars-after-launch-of-first-biosimilar-in-10-b-canadian-market-retail-bulls-charge-in/chFjax5Rchk">introduced</a> its first biosimilar drug, Niopeg, to the Canadian market, to treat the risk of infection in cancer patients undergoing chemotherapy. In June, a generic version of Neurontin, Gabapentin, was launched for treating neuropathic pain and epilepsy.SBFM stock is down by 29% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-draws-investor-interest-as-european-regulator-reportedly-terms-door-safety-a-priority/ch6p3LDR3nA">Tesla Stock Draws Investor Interest As European Regulator Reportedly Terms Door Safety A Priority</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.

Equity

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.


Retail chatter around Sunshine Biopharma surged late Wednesday after the company introduced Niopeg, its first biosimilar drug, into the Canadian market,&nbsp;sending its stock soaring by nearly 14% — its best session in over seven months.The treatment, developed by its subsidiary Nora Pharma, is a pegfilgrastim biosimilar to Neulasta, which is commonly used to reduce the risk of infection in cancer patients undergoing chemotherapy.Niopeg is supplied in a 6mg/0.6mL prefilled syringe and is designed for patients with non-myeloid cancers.&nbsp;The company noted that global demand for Neulasta and similar drugs was worth approximately $4.5 billion last year, with expectations that it could rise to $9.2 billion by 2033, driven by increasing cancer cases and wider chemotherapy use.Canada, although a smaller part of the global market, still plays a disproportionately large role in biologics spending, according to a statement released by the company.&nbsp;The company said that Canada’s biologic drug sales totaled approximately $10 billion in 2020, accounting for roughly one-third of all pharmaceutical expenditures. Biosimilars, such as Niopeg, have gained more traction there in recent years, helped by provincial policies that encourage switching from branded biologics.The launch follows last month’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-unit-launches-generic-anticonvulsant-in-canada/chlayAARbC6">rollout of a generic version of Gabapentin</a>, a standard treatment for neuropathic pain and epilepsy, now available in 100 mg, 300 mg, and 400 mg doses, packaged in bottles of 500 capsules.Sunshine Biopharma states that it currently has 72 generic drugs on the Canadian market and plans to introduce more before the end of the year. It’s also pursuing drug candidates in areas such as liver cancer and treatments related to the coronavirus.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/SBFM">Sunshine Biopharma</a> was ‘extremely bullish’ amid a 6,200% jump in 24-hour message volume.One user noted that for the first time in a long while, Sunshine Biopharma was holding onto its gains following a news release, calling the chart setup strong and suggesting the stock could be gearing up for a multi-day run.<stembedurl>https://stocktwits.com/Tryitin/message/619793472</stembedurl>Another user pointed to the significance of the product launch into a $10 billion market and expressed confidence that the stock could see substantial upside in the coming days, even speculating about a potential move into double digits.<stembedurl>https://stocktwits.com/Tryitin/message/619760589</stembedurl>The stock has declined 42.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In

The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.

Shares of Sunshine Biopharma Inc. (SBFM) were in the spotlight on Wednesday after the pharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/06/20250611_SBFM_Press-Release_Launches-Gabapentine-1.pdf">announced</a> that its Canadian unit, Nora Pharma, has launched a new generic prescription drug, Gabapentin.Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy, as well as for the treatment of pain caused by various medical conditions by reducing excess excitation of the neural networks in the brain and spinal cord.Nora Pharma’s Gabapentin is available in strengths of 100 mg, 300 mg, and 400 mg and comes in bottles of 500 capsules.According to Sunshine Pharma, Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin, which was valued at $1.92 billion in 2024. It is projected to reach $3.07 billion, the company said.CEO Steve Slilaty said that the company is attempting to fortify its presence in Canada’s generic drugs market, valued at $9.4 billion. The market is forecasted to nearly double to $19.2 billion by 2032, he added.Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada, with over 12 additional drugs planned for launch in the remainder of 2025.On Stocktwits, retail sentiment around SBFM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_1_14_32_PM_png_31faf5b9e5.webp" alt="SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits" width="631" height="67"><figcaption>SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that short sellers will not risk shorting Sunshine owing to its significant institutional ownership, low float, and ‘HUGE potential.’<stembedurl>https://stocktwits.com/LH1975New/message/617532142</stembedurl><a href="https://stocktwits.com/symbol/SBFM">SBFM stock</a> is down by about 46% this year and has wiped out nearly three-quarters of its valuation over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-rises-on-partnership-with-smartox/chlaUpbRbCy">Intelligent Bio Rises On Partnership With Smartox To Expand US Market Presence: Retail Hopes The Stock To Hit $2.6</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.

Sunshine Biopharma, Inc.'s stock rose over 3% on Monday, lifting retail investor sentiment, after the company said its Canadian subsidiary had launched a generic version of an oncology drug.Nora Pharma launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market, Sunshine said.&nbsp;The drug is indicated for advanced renal cell carcinoma, breast cancer in certain post-menopausal women, some neuroendocrine tumors and tuberous sclerosis-related brain tumors.&nbsp;Sunshine said Everolimus is available in 2.5 mg, 5 mg and 10 mg strengths in 30-tablet blister packs.The global Everolimus market is valued at $2.5 billion in 2023 and is projected to hit around $4.8 billion by 2032, the company said.&nbsp;The announcement sent message volume on Stocktwits about Sunshine Biopharma soaring over 14,700% in the 24 hours to late Monday, even as the stock slid over 1% in after-hours trading.Sentiment among retail traders flipped to ‘extremely bullish’ from ‘bearish’ a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SBFM_sentiment_and_message_volume_as_of_April_21_png_ee65768271.webp" alt="SBFM sentiment and message volume as of April 21.png" width="1318" height="316"><figcaption>SBFM sentiment and message volume as of April 21. | source: Stocktwits</figcaption></figure>One watcher took heart from Everolimus' sales projections and said it "is going to blow someday."<stembedurl>https://stocktwits.com/JdNews/message/612158515</stembedurl>Another user speculated that the company was soon going to form strategic partnerships.<stembedurl>https://stocktwits.com/contra7/message/612209836</stembedurl>Earlier this month, Sunshine reported new preclinical data for its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma (HCC).&nbsp;Sunshine’s stock, which has a short interest of 6.6% according to Koyfin, has lost over half its value this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

How Is The Market Feeling About Sunshine Biopharma?

12 titoli sanitari in movimento, sessione regolare del 01/04/2024

Titoli in rialzo
Le azioni di Sunshine Biopharma (NASDAQ:SBFM) hanno fatto segnare +84,29% a 0,11 dollari durante la sessione regolare di luned .
Le azioni di Xilio Therapeutics (NASDAQ:XLO) sono...

12 acciones de salud en movimiento en la sesi n intrad a del 01/04/2024

Acciones al alza
Sunshine Biopharma (NASDAQ:SBFM) se anotaron un alza del 93,22% para establecerse en los 0,12 d lares durante la sesi n del regular del lunes.
Xilio Therapeutics (NASDAQ:XLO) ganaron...

Sunshine Biopharma reports 2023 EPS (19c) vs. ($1.76) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

12 acciones de salud en movimiento durante la preapertura del 01/04/2024

Acciones al alza
Sunshine Biopharma (NASDAQ:SBFM) experimentaron un repunte del 62,14% para establecerse en los 0,10 d lares durante la sesi n del pre-market del lunes.
Galera Therapeutics...

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sales Grew at an Average Rate of 14% Per Quarter During the YearNEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the 'Company'), a pharmaceutical company offering...

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Current Price	$1.39
Prev Close	$1.41
Open	$1.44
Dividend Yield	0.00%
50-Day Moving Average	$1.67
Beta	1.81
Avg. Volume	1.94M
PE Ratio	-0.76

52-Week High	$3.90
52-Week Low	$1.17
Market Capitalization	$6.92M
EPS (Annual)	-$7.32
Price to Book	0.27
Revenue Per Employee	$670,659.29
Enterprise Value/EBITDA	N/A

SBFM
Sunshine Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SBFM News

SBFMSunshine Biopharma Inc